AEON Biopharma
AEON
22 hedge funds and large institutions have $9.22M invested in AEON Biopharma in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
229% more capital invested
Capital invested by funds: $2.8M → $9.22M (+$6.41M)
25.2% more ownership
Funds ownership: 23.47% → 48.67% (+25%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8% less funds holding
Funds holding: 24 → 22 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$8.33M |
| 2 |
SG
StoneX Group
New York
|
+$15.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.9K |
| 4 |
Citigroup
New York
|
+$5.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$20.1K |
| 2 |
Jane Street
New York
|
-$16.1K |
| 3 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
-$827 |
| 4 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$100 |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$58 |
AEON Hedge Fund Activity: Q2 2026 in Review
22 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q2 2026, worth a combined $9.22M — up 229% from $2.8M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of AEON and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Dauntless Investment Group, adding an estimated $8.33M. The largest seller was XTX Topco, exiting entirely with an estimated $20.1K sold.
- 22 institutional investors held AEON Biopharma (AEON) as of Q2 2026, down from 24 in Q1 2026.
- Funds reported $9.22M of AEON Biopharma stock for Q2 2026, up 229% quarter-over-quarter.
- 2 funds opened new AEON Biopharma positions in Q2 2026 and 4 closed out, a net change of -2 holders.
- The largest AEON Biopharma buyer in Q2 2026 was Dauntless Investment Group, an estimated $8.33M added.
- The largest AEON Biopharma seller in Q2 2026 was XTX Topco, an estimated $20.1K sold.
Based on aggregated 13F filings for Q2 2026.